Focused on accelerating the path from “Idea to Utilization,” I2U is an initiative, made possible by Novartis Canada, committed to identifying and addressing the barriers and obstacles impeding the uptake of breakthrough medicines across Canada. Securing reimbursement is an essential first step, but maximizing the value of certain technologies often requires significant health system changes. By engaging patients, payers, policymakers and practitioners, I2U will help to provide Canadian health system leaders with the tools and insights they need to ensure optimal implementation.
On Thursday, June 1 the I2U Panel Discussion unpacked the lessons from Canada’s experience with CAR-T technologies to make the case for a new approach to maximizing the system value of breakthrough medicines.